Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2007-A01009-44 | Registry Identifier | RCB |
Not provided
Not provided
Not provided
Administrative re-organization of the department. Referent physician left the hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The physio-pathology of Alzheimer's disease (AD) remains unknown and there is no cure. Thus, the search for objective markers of preclinical first signs of cognitive impairment, is currently a major public health issue. Early detection of the disease is a major challenge to hope to slow or even stop the neurodegenerative process before the stage of dementia.
In AD the investigators observe:
Recent publications show that cerebrospinal fluid (CSF)flow is also altered, probably due to dysfunction of the choroid plexus. Hence the potential interest to study is, in addition to conventional imaging, the imaging of CSF dynamics and choroid plexus metabolism. In that aim,the investigators use two imaging modalities:
The investigators expect that, because of choroid plexus atrophy in AD, CSF flow would be altered as well as glucose metabolism dynamic in choroid plexus.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alzheimer | Experimental | Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations. |
|
| Vascular dementia | Experimental | Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations. |
|
| Mild cognitive impairment (MCI) | Experimental | Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations. |
|
| Healthy subjects (MRI) | Experimental | Healthy subjects agreeing to undergo magnetic resonance imaging examination. |
|
| Healthy subjects (PET) | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Magnetic resonance imaging | Other | CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus. |
| Measure | Description | Time Frame |
|---|---|---|
| Dynamic FDG (fluoro-deoxyglucose) PET | Extraction of tissue time-activity curves ; notably in choroid plexus. | Day 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Aqueductal CSF flow | Measurement of CSF flow at the Sylvius' aqueduct level. Calculation of the corresponding stroke volume. | Day 1 |
| Follow-up MRI | MRI examination of MCI patients after one year in order to assess CSF flow differences in MCI how converted to Alzheimer. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marc-Etienne MEYER, MD,PhD | CHU Amiens | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Rouen | Rouen | Haute Normandie | 76000 | France | ||
| CHU Amiens |
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D060825 | Cognitive Dysfunction |
| D015140 | Dementia, Vascular |
| D019636 | Neurodegenerative Diseases |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
Not provided
Not provided
| ID | Term |
|---|---|
| D009682 | Magnetic Resonance Spectroscopy |
| ID | Term |
|---|---|
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
|
|
| Positron emission tomography | Other | Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus. |
|
|
| Day 365 |
| Follow-up PET | Dynamic FDG PET examination of MCI patients after one year in order to assess FDG dynamic evolution in MCI how converted to Alzheimer. | Day 366 |
| Amiens |
| Picardie |
| 80054 |
| France |
| D019965 |
| Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D003072 | Cognition Disorders |
| D002561 | Cerebrovascular Disorders |
| D002537 | Intracranial Arteriosclerosis |
| D020765 | Intracranial Arterial Diseases |
| D056784 | Leukoencephalopathies |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |